Samsung Biologics signs a contract manufacturing agreement of KRW 17.8 billion with U.S. pharma
Samsung Biologics announced conclusion of a contract manufacturing agreement with a U.S. pharmaceutical company on 21 February.
The agreed payment is approximately KRW 17.8 billion(6.06% of recent sales), and the start date of the agreement is 21 February.
The term of the agreement is confident...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
